Roble Belko & Company’s Avanos Medical AVNS Stock Holding History

Roble Belko & Company’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1	Closed	–	–	290
2017 Q2	$0	Buy	+1	New	+$38	﹤0.01%	301

Other funds holding AVNS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Roble Belko & Company's AVNS Position: Q3 2017 in Review

Roble Belko & Company sold out of Avanos Medical (AVNS) in Q3 2017, closing a stake of 1 share.

Roble Belko & Company first reported a position in AVNS in Q2 2017 and held it in 1 quarter. The position peaked at $0 in Q2 2017. 318 funds tracked by Wall St. Rank hold AVNS as of Q3 2017.

Roble Belko & Company reported no remaining Avanos Medical position as of Q3 2017 after selling out during the quarter.
Roble Belko & Company sold 1 Avanos Medical share in Q3 2017.
Roble Belko & Company first reported a position in Avanos Medical in Q2 2017 and held it in 1 quarter.
Roble Belko & Company's Avanos Medical position peaked at $0 in Q2 2017.
318 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2017.

Based on Roble Belko & Company's 13F filing for Q3 2017, filed 8 Nov 2017.